Current perspectives of limbal-derived stem cells and its application in ocular surface regeneration and limbal stem cell transplantation

Vivek Singh1 | Anil Tiwari2,3 | Abhinav Reddy Kethiri1 | Virender Singh Sangwan3

1Stem Cell Biology Laboratory, Center for Ocular Regeneration, L V Prasad Eye Institute, Hyderabad, India
2Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
3Department of Cornea and Uveitis, Dr. Shroff’s Charity Eye Hospital, New Delhi, India

Correspondence
Virender Singh Sangwan, MBBS, MS, Cornea, Anterior Segment and Uveitis, Dr. Shroff’s Charity Eye Hospital, Daryaganj, New Delhi, India.
Email: virender.sangwan@sceh.net

Abstract
Limbal stem cells are involved in replenishing and maintaining the epithelium of the cornea. Damage to the limbus due to chemical/physical injury, infections, or genetic disorders leads to limbal stem cell deficiency (LSCD) with partial or total vision loss. Presently, LSCD is treated by transplanting limbal stem cells from the healthy eye of the recipient, living-related, or cadaveric donors. This review discusses limbal-derived stem cells, the importance of extracellular matrix in stem cell niche maintenance, the historical perspective of treating LSCD, including related advantages and limitations, and our experience of limbal stem cell transplantation over the decades.

KEYWORDS
corneal stromal stem cells, cultivated limbal epithelial transplantation, limbal stem cell deficiency, limbus, simple limbal epithelial transplantation, stem cells

1 INTRODUCTION

Stem cells have the self-renewal ability and potency to differentiate into specific cell types or an entire organism. Adult stem cells (ASCs) are populations of cells involved in an internal repair mechanism generating replacement for cells lost through the wound healing process, wear and tear, injury, and diseases.1 They reside at specific anatomical locations and may remain quiescent for long periods until activated by their need to maintain tissue homeostasis.2 Stem cells for the cornea are present at the corneoscleral limbus. Two populations of ASCs exists in the limbal niche, epithelial and stromal stem cells, referred as limbal epithelial stem cells (LESCs)3 and corneal stromal stem cells (CSSCs),4 respectively. These stem cell populations are essential to maintain corneal transparency.5 Additionally, the limbal niche also harbors early transient amplifying cells, melanocytes, and Langerhans cell.6-8 As per the recent global consensus by the International Limbal Stem Cell Deficiency Working Group, they concluded that “Autologous limbal stem cell transplantations using the least amount of donor tissue, such as simple limbal epithelial transplantation (SLET), ex vivo-cultivated autologous LSC, and modified conjunctival limbal autograft (CLAU), are preferred over other surgical treatments for unilateral or subtotal bilateral limbal stem cell deficiency (LSCD) or whenever feasible because of better long-term outcomes and fewer complications.”9

This review summarizes the recent significant progress based on our experience and literature survey on ocular surface stem cells, their culture and expansion, corneal epithelial regeneration, limbal stromal cells, and the role of limbal niche. We have also discussed the associated challenges and need of various stem cells in ocular therapies.
2 CULTURE AND EXPANSION OF LIMBAL-DERIVED STEM CELLS

Limbal stem cells are the well-characterized cells of the ocular surface other than conjunctival progenitors whose anatomical location remains elusive. LESCs and CSSCs can be admirably identified in vitro with different morphological and slow-cycling properties of the cells. Limbal epithelial cultures used for transplantation in treating ocular surface burns are known to contain stem cells that are identified by the positive expression of the p63 and ABCG2. The recent discovery of ABCB5 as a marker for limbal stem cells and its tendency to localize with p63 could aid in exclusive isolation of stem cell populations in limbus. The properties of LESCs were further retained or enhanced by their culture on feeder layers that includes gamma-irradiated 3T3 cells, human embryonic fibroblasts, or human amniotic epithelial cells. Interestingly, intrinsic feeder layers were also observed in limbal epithelial cultures that help in the maintenance of the stemness in the limbal explant culture system.

2.1 Limbal epithelial cells

In vitro cell expansion potential of the limbal tissues had revealed that tissue obtained from living subjects had a higher capability to initiate cell growth than the preserved cadaver tissues. This decrease in cell viability of the cadaver tissues could be attributed to preservation outside their nativity. Whereas better cell growth with fresh tissue than cadaver tissue is comprehensible, it seems that limbal stem cells remain viable in the limbal niche during storage of cadaver corneal tissue for weeks. We had also observed from our study that 60% of the cadaver tissues were able to initiate the cell growth in contrast to 90% of the live tissues. Interestingly, these cadaver tissues that have initiated cell growth compete with the live tissue in terms of cell expansion and epithelial cell integrity, demonstrating viable limbal stem cell populations despite preservation. Moreover, the epithelial cell sheets developed from the limbal explants ex vivo showed greater integrity, as evident from the rich development of desmosomes, hemidesmosomes, and E-cadherins.

Furthermore, a study reported by Ekpo et al had cultured the cadaver tissues adjacent to the limbus, that is, toward corneal (L.cor) and conjunctival (L.conj) sides. Interestingly, they have noted that the cells cultured from the L.conj had more growth potential and stemness than L.cor, as evident from p63α expression. Though live limbal tissue has desirable cell growth, cadaver limbal rims obtained either during corneal keratoplasties or from stored eye banking tissues also serves as a viable alternative for transplantation purposes.

2.2 Limbal niche cells

CSSC exhibits mesenchymal stem cell-like properties, although they are of neurocrest origin and are identified as side population cells expressing ABCG2 and PAX6. While CSSCs are multipotent mesenchymal cells, LESCs are confined to deriving corneal/limbal epithelium. Though the primary culture of CSSS survives longer passages (40-50), they may lose their plasticity with the increase in senescence and therefore are preferred at earlier passages in cell therapies. Our in vitro experiments of limbal cultures had shown that these cells are predominantly identified as a streak at the expanding edge of the expressing ABCG2 (Figure 1A,B). In enzymatically digested limbus tissue cultures, we observed that the stromal cells emerge from the epithelial sheet at late stages of culture, which are evidently visible in further passages (Figure 1C,D).

Ex vivo culture of the limbal tissue used for transplantation involves the use of irradiated murine fibroblasts as feeder layers, fibrin sealant, or the human amniotic membrane (AM) as a scaffold for cell growth. While feeder layers have the risk of xenogeneicity, AM carries the risk of disease transmission and batch variations. However, no adverse events have been reported in the use of different substrates. Recent studies have shown that fiber hydrogel and serum-free media synergize to provide an optimal environment for keratocyte phenotype growth as well as the regeneration of damaged corneal stroma. Interestingly, stromal cells cultured on two-dimensional (2D) silk fibroin sheets and stacked to provide three-dimensional (3D) structure leverages both 3D microenvironment and stromal cell sufficiency.

3 EXTRACELLULAR MATRIX NICHE FOR ENHANCED CELL THERAPY

The extracellular matrix (ECM) harboring ASCs comprises adhesion proteins, proteoglycans, polysaccharides, and structural proteins: fibronectin, laminin, and tenascin-c. The shape and composition of ECM depend upon the tissue, developmental stages, and pathological conditions, thereby affecting the overall fate of the stem cells. ECM orchestrates the native 3D environment surrounding ASCs, and neighboring cells and also serves as an active reservoir of soluble factors, thereby modulating cellular behavior. Besides being a dynamic

Significance statement

Limbal stem cells are the adult stem cells located in the basal epithelial layer of the corneal limbus that aid in the renewal of the corneal epithelium. Damage to limbal stem cells affects corneal epithelial regeneration and the subsequent invasion of conjunctival epithelium and neovascularization of the corneal surface. This causes a disease called limbal stem cell deficiency, which leads to blindness in the cornea. This article summarizes the types of stem cells present in the limbus and their cell culture techniques. Recent advancements in stem cell treatment for corneal pathologies are discussed, with historical outlook and clinical significance.
microenvironment. ECM provides biophysical properties essential for ASC maintenance. In the case of ocular surface wounds that may destroy the limbal niche, revitalization of the microenvironment along with limbal cell transplantation had shown promising results. It has been well established that stem cells thrive in 3D structures (cell spheres) and differentiate in two-dimensional cultures. Therefore, 3D reconstruction of the limbal niches had gained attention in fabricating artificial corneas or scaffolds to support stem cell maintenance. Additionally, replacement of damaged ECM with AM or bioengineered ECM would provide enhanced cell therapies. Therefore, it is essential to understand the ASC-ECM interaction in maintaining niche, which provides a conducive milieu for in vitro expansion of ASCs. Understanding the specific components of ECM, its role in regulating stem cell behavior in different tissues can be deciphered from the in vivo studies and with the use of engineered in vitro niche. Similarly, ECM is vital for the physiological renewal of the ocular surface/limbal microenvironment and plays a crucial role in the function and maintenance of the limbal niche. The limbal niche comprises well-organized ECM, signaling drivers, and niche cells such as melanocytes, immune cells, vascular cells, nerve cells, and stromal cells, which are compromised in certain hereditary conditions or severe insults to the limbus. Bioengineered corneas are fabricated using polyethylene glycol to generate a niche like structure or entire corneal stroma with keratocytes embedded in them. Porous hydrogels similar to collagen structure were also developed by the Griffith’s group that amalgamates with natural fibrin compound to form LiQD corneas. These studies will potentially open new avenues for creating more accurate in vivo niche features by applying in vitro system, enabling a better understanding of the biology and efficacy of stem cell-based therapies.

4 | HISTORICAL PERSPECTIVE AND PROGRESSIVE SHIFT IN LIMBAL STEM CELL TRANSPLANTATION

The concept of limbal stem cells in treating LSCD was clinically applied by Kenyon and Tseng, where the conjunctiva with limbus tissue was used for ocular surface reconstruction in patients with chemical injuries. Since then, chemical burns of the eye had been challenging with complexity and variation among the patients. Much emphasis has been given to understand the extent of LSCD firsthand before deciding on the therapeutic approach. Clinical presentation of ocular surface chemical burns has been graded using either Roper-Hall’s or Dua’s classification to understand the extent of limbal tissue damage. With further clinical advancements, in vivo confocal
microscopy identifies specific cell types for accurate diagnosis of LSCD. Apart from the severity of chemical burns, other factors such as lid deformities, tear film abnormalities, and inflammation control have been key factors in managing LSCD.

Therapeutic options for LSCD include CLAU that involves healthy conjunctival and limbal tissue patches obtained by sectoral excision from the donor and transplanted in to the affected eye. Kerato-limbal allograft mimics CLAU except for the donor tissue source used, usually a cadaver tissue or living-related donor and requires immunosuppression. Amniotic membrane grafting (AMG) is a simpler technique used for acute cases of chemical burn that reduces inflammation and promotes healing and scar-free regeneration of the epithelium. AMG could also be applied in conjunction with other therapeutic cells for better efficacy. Currently, cell-based therapies such as cultivated limbal epithelial transplantation (CLET) and SLET are the preferred choice for better clinical outcomes and less donor complications.

With the drawbacks of obtaining larger grafts and risking the donor eye in CLAU, Pellegrini et al had generated corneal epithelium by ex vivo serial cultivation of cells using a 1 to 2 mm² autologous or cadaver limbal donor tissue on irradiated 3T3 cells. These cells were further transplanted on the patient’s affected eye giving rise to the technique of CLET. The cell growth substrate was later modified to the AM, which avoids the xenogenicity in transplantation. The advantage of CLET is the ex vivo increase of cell population that could be assessed for cell phenotypes and the percentage of stem cell pool ascertaining the successful outcomes of CLET. Besides, any gene related defects could be corrected and then transplanted in CLET. The largest case series of CLET had reported success rates of 71% (142 of 200 eyes), 76% (443 of 583 eyes), or 70% (815 of 1164 eyes) with key successful outcomes as the transparent and avascular cornea. In cases where CLET fails, a repetitive surgery of the same had demonstrated a success rate of 66% (33 of 50 eyes) with improvement in vision by 76%. Additionally, the long-term follow-up of CLET in two individual studies reported a survival rate of 76.6% 10 years after the surgery, indicating the cell sustainability and maintenance of corneal homeostasis. Overall, CLET is a proven successful technique to treat LSCD with a shortened time of corneal re-epithelialization, repeatability of the procedure, and rare donor complications. Therefore, commercial marketing of this technique as “Holoclar” has been approved by the European medical agency for treating LSCD. Holoclar uses the patient’s own (autologous) limbal stem cells to treat unilateral LSCD. Studies by Luca and Pellegrini showed that the clinical success of Holoclar treatment had a positive correlation with the percentage of holoclones present in the limbal culture. Many other groups worldwide have used limbal cultures to treat ocular burns, often with different culture systems.

With the knowledge and experience from CLET, our group had developed SLET, a novel method of expanding the limbal cells in vivo directly on the patient’s affected eye while continuing the use of AM as substrate. This technique involves spreading AM on the ocular surface after removing the fibrovascular pannus and placing small pieces of donor limbal tissues uniformly over the corneal surface (Figure 2). Cell outgrowth from the limbal explants on the ocular surface after SLET merges into each other similar to in vitro cell expansion and corneal re-epithelialization typically happens in 2 weeks. Initial surgery with six patients had demonstrated 100% success at 6 months follow-up. This strategy is similar to epidermal skin grafting where small skin tissue pieces spread across the larger wounded areas promotes skin pigmentation/re-epithelialization. A large, single-center case series of at least 1 year follow-up has shown a 76% (95 of 125 eyes) success rate with 75% improvement in the patients’ visual acuity and a median follow-up of 1.5 years. Another multicenter analysis had shown an 84% (57 of 68 eyes) success rate at 1 year follow-up. SLET, when compared to CLAU, had similar success rates and ocular surface parameters postsurgery. Failure of SLET had most likely appeared in the first 6 months after the surgery. Loss of the transplanted grafts is also associated with the recurrence of conjunctivalization and failure of SLET. In our experience, risk factors of transplantation failure include preoperative conditions of the patient such as dryness of the eye, unaddressed pre-existing conditions such as symblepharon involvement or lid deformities, persistent epithelial defects, and simultaneous penetrating keratoplasty. AM also stands as a critical factor in the success of SLET since the limbal explant growth and survival is dependent on the AM.

Ex vivo cultivation of the corneal epithelial cells from limbal tissue requires a cell culture laboratory, and therefore CLET is an expensive procedure with less patient outreach due to lack of facilities in the hospital setting and ethical regulations. SLET, on the other hand, does not need a cell culture laboratory and is also a single-stage surgery making it inexpensive to CLET. Importantly, SLET has comparable or even better results compared to CLAU and CLET, in addition to the ease of ophthalmologists to perform this surgical technique. Additionally, SLET is being used to manage ocular surface disorders such as pterygium or ocular surface squamous neoplasia that involves damage to the limbus. Limitations of SLET are in cases of persistent epithelial defects observed even after multiple surgeries, and therefore, CLET can be considered in such cases to provide adequate epithelial cells. Additionally, SLET is usually avoided or is combined with CLAU in reconstruction of a complex ocular surface or severe symblepharon. In cases of bilateral LSCD, allogeneic CLET/SLET are available, which carries a greater risk of rejection and eventual
FIGURE 2  Clinical photographs showing the surgical technique of limbal biopsy from the donor eye and transplantation of the limbal tissue on the recipient eye. A, A 2 × 2 mm area is marked across the superior limbus of the donor eye. B, A subconjunctival dissection is carried out 1 mm into the clear cornea. C, The limbal tissue is excised. D,E, A peritomy is performed and the fibrovascular pannus is excised from the recipient ocular surface. F, A human amniotic membrane graft is placed on the bare ocular surface and secured to it with fibrin glue. G,H, The donor limbal tissue is cut into 8 to 10 small pieces and secured to the amniotic membrane overlying the cornea with fibrin glue. Reprint from Sangwan et al.62

TABLE 1  Advantages and limitations of surgical techniques to treat limbal stem cell deficiency

| Technique       | Source of tissue                                      | Benefits                                                                 | Limitations                                                                 | Reference |
|-----------------|-------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------|
| CLAU            | Conjunctiva and limbus                                | Larger patch of conjunctiva can be used for ocular surface reconstruction | Larger limbal grafts, risk at donor site complications                     | 75        |
| AMG             | Amniotic membrane obtained during cesarean            | Anti-inflammatory properties, no immune rejection, natural biological patch | Storage and risk of disease transmission                                   | 76        |
| CLET            | Limbal biopsy                                         | Smaller donor limbal tissue. Characterization and increasing the number of epithelial or stem cells. Epithelial cell sufficiency in recurrent epithelial defects, Gene editing | Cell culture expert dependency. Cost involved in maintenance of CGMP facility and hence increase in surgical costs. | 13        |
| SLET            | Limbal biopsy                                         | No requirement of a CGMP facility. Single stage procedure. Smaller donor limbal tissue. | Risk of loss of donor limbal tissue. Not suitable for persistent epithelial defects or ocular surface reconstruction. | 62, 67    |
| COMET           | Oral buccal mucosal epithelium                        | Treatment of bilateral LSCD. Can avoid allogeneic immunosuppression       | Poor differentiation to corneal epithelial cell type. Risk of dry-eye conditions. | 77, 78    |
| Keratoprosthesis| Biological (dental or osteo), Biocompatible (polymethyl methacrylate) with cadaver cornea | Treatment of bilateral LSCD, Immediate vision                             | Frequent conjunctivalization, risk of glaucoma                              | 79        |
| iPSC            | Skin punch biopsy                                     | Ability to generate mature corneal epithelium or organoids. Autologous tissue can be used in bilateral LSCD. | Risk of tumorigenic potential. Requirement of robust cell characterization. | 74        |
| Mesenchymal stem cells | Bone marrow                                         | Sufficiency of autologous tissue for transplantation. Anti-inflammatory properties. | Cannot differentiate to corneal epithelial cells                            | 80, 81    |

Abbreviations: AMG, amniotic membrane grafting; CGMP, Current Good Manufacturing Practice; CLAU, conjunctival limbal autograft; CLET, cultivated limbal epithelial transplantation; COMET, cultivated oral epithelial mucosal transplantation; iPSC, induced pluripotent stem cell; LSCD, limbal stem cell deficiency; SLET, simple limbal epithelial transplantation.
requirement of immunosuppression. Cultivated oral epithelial mucosal transplantation (COMET) serves as a better redressal to treat bilateral LSCD with no immune suppression requirement. Nevertheless, persistent epithelial defects and graft failure were higher in COMET compared to allo-CLET.73

With the advent of CLET and SLET, several other cell sources are also being explored in treating LSCD. Specifically, induced pluripotent stem cells (iPSCs) offer a promising approach to generate mature corneal/limbal epithelium with 3D corneal organoids.74 Once standardized, iPSC-derived corneal/limbal epithelial cells could be an unlimited source for limbal cell therapies. However, all these techniques have their advantages and limitations (Table 1) and are used depending on the condition of the patient. Furthermore, noncellular therapies such as patient-derived hemo or AM derivatives and soluble growth factors are the emerging approaches in the regeneration of the ocular surface in circumventing allogeneic complications.82 Another impending, potent source of stem cells for treating LSCD is the limbal stromal-derived cells. Though these cells were not characterized during CLET, they were concealed constituent of the cultures and could have played a role in wound healing after transplantation. Gene expression profiles of the isolated limbal cultures derived stromal cells had similar expression profiles to bone marrow-derived mesenchymal cells.23 These stromal cells isolated from peripheral cornea or limbus also showed keratocyte markers’ expression and could differentiate to chondrogenic or adipogenic cells,12,24 similar to mesenchymal cells. Basu et al had derived the human limbal biopsy stromal cells and transplanted them on the wounded mice cornea with successful prevention of scars indicating the role of stromal fibroblasts in rearranging the stromal ECM. Moreover, these cells were also capable of reversing the already existing scars into a clear cornea, as evident in nitrogen injured scar models of mice.63 Interestingly, the collagen reorganization of the wounded mice cornea and the lamellar structure was indistinguishable from the normal cornea making the limbal stromal cells a potent therapeutic for treating corneal stromal blindness.84 The immunomodulation ability of limbal stromal-derived cells makes them an excellent source for treating corneal scars and acute chemical injuries of the cornea.

5 | CONCLUSION

The biggest challenge for the stem cell culture-based therapies lies in the availability of eye bank tissue, AM, maintenance, transportation, and costs involved in the stem cell culture. Besides, maintenance of cells in the long-term storage and expansion of these cells for clinical use may alter their stem cell properties. After all, the current regulatory hurdle and Good Manufacturing Practice (GMP) compliance take a long time, and the costs involved are enormous; therefore, SLET (for LSCD) still seems very promising and cost-effective. For many other incurable corneal pathologies, CSSCs or the bone marrow-derived stem cells would help overcome the limitations of limbal transplantation. The need of the hour is reliable, stable, and over the shelf treatment for corneal perforation, haze, and inflammation, including ocular stem cell deficiency like the teardrop bottle.

ACKNOWLEDGMENTS

We would like to thank Shroff’s Charity Eye Hospital for proving necessary infrastructure and financial support to V.S.S. We would also like to thank Hyderabad Eye Research Foundation and Science and Engineering Research Board (SERB), India (EMR/2017/005086) for proving necessary support to V.S. V.S. would also like to acknowledge SERB for providing the CORE research grant (CRG/2018/003514). Additionally, A.R.K. acknowledges Indian Council of Medical Research for providing the senior research fellowship (5/3/8/54/ITR-F/2018-ITR).

CONFICT OF INTEREST

The authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

V.S.: conception and design, financial support, administrative support, collection and/or assembly of data, provision of study material or patients, data analysis and interpretation, manuscript writing, final approval of manuscript. A.T., A.R.K.: collection and/or assembly of data, data analysis and interpretation, manuscript writing. V.S.S.: conception and design, financial support, administrative support, provision of study material or patients, data analysis and interpretation, manuscript writing, final approval of manuscript.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Vivek Singh https://orcid.org/0000-0003-3958-5635
Virender Singh Sangwan https://orcid.org/0000-0002-8229-4158

REFERENCES

1. De Luca M, Aiuti A, Cossu G, et al. Advances in stem cell research and therapeutic development. Nat Cell Biol. 2019;21:801-811.
2. Mimeault M, Batra SK. Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev. 2008;4:27-49.
3. Cottereil G, Cheng SZ, Dong G, Sun TT, Lavker RM. Existence of slow-cycling limbal epithelial basal cells that can be preferentially stimulated to proliferate: implications on epithelial stem cells. Cell. 1989;57:201-209.
4. Funderburgh JL, Funderburgh ML, Du Y. Stem cells in the limbal stroma. Ocul Surf. 2016;14:113-120.
5. Ghoubay-Benallaoua D, de Sousa C, Martos R, et al. Easy xeno-free and feeder-free method for isolating and growing limbal stromal and epithelial stem cells of the human cornea. PLoS One. 2017:12:e0188398.
6. Guo ZH, Zhang W, Jia YYS, Liu Q, Li Z, Lin J. An insight into the difficulties in the discovery of specific biomarkers of limbal stem cells. Int J Mol Sci. 2018;19:1982.
7. Dua HS, Shanmuganathan VA, Powell-Richards AO, Tighé PJ, Joseph A. Limbal epithelial crypts: a novel anatomical structure and a putative limbal stem cell niche. Br J Ophthalmol. 2005;89:529-532.
8. Shortt AJ, Secker GA, Munro PM, Khaw PT, Tuft SJ, Daniels JT. Characterization of the limbal epithelial stem cell niche: novel imaging techniques permit in vivo observation and targeted biopsy of limbal epithelial stem cells. 

9. Deng SX, Kruse F, Gomes JAP, et al. Global consensus on the management of limbal stem cell deficiency. 

10. Gonzalez G, Sasamoto Y, Ksander BR, et al. Limbal stem cells: identity, developmental origin, and therapeutic potential. 

11. Qi H, Zheng X, Yuan X, Pflugfelder SC, Li DQ. Potential localization of putative stem/progenitor cells in human bulbar conjunctival epithelium. 

12. Polisetty N, Fatima A, Madhira SL, Sangwan VS, Vemuganti GK. Mesenchymal cells from limbal stroma of human eye. 

13. Rama P, Matuska S, Paganoni G, Spinelli A, de Luca M, Pellegrini G. 

14. Vemuganti GK, Fatima A, Madhira SL, et al. Limbal stem-cell therapy and long-term corneal regeneration. 

15. Ksander BR, Kolovou PE, Wilson BJ, et al. ABCB5 is a limbal stem cell transporter identifies a population of clonogenic human limbal epithelial cells. 

16. Gonzalez S, Deng SX. Presence of native limbal stromal cells increases corneal limbal epithelial repair. 

17. Polisetty N, Zenkel M, Menzel-Severing J, Kruse FE, Schlötzer-Schrehardt U. Cell adhesion molecules and stem cell niche-interactions in the limbal stem cell niche. 

18. James SE, Rowe A, Ilari L, Daya S, Martin R. The potential for eye bank limbal rings to generate cultured corneal epithelial allografts. 

19. Kethiri AR, Basu S, Shukla S, Sangwan VS, Singh V. Optimizing the role of limbal explant size and source in determining the outcomes of limbal transplantation: an in vitro study. 

20. Ekpo P, Inthasin N, Matamnan S, et al. Characterization of cultured limbal epithelial cells. 

21. Utheim OA, Pasovic L, Raeder S, et al. Effects of explant size on epithelial outgrowth, thickness, stratification, ultrastructure and phenotype of cultured limbal epithelial cells. 

22. Polisetty N, Agarwal P, Khan I, Kondaiah P, Sangwan VS, Vemuganti GK. Gene expression profile of epithelial cells and mesenchymal cells derived from limbal explant culture. 

23. Rama P, Matuska S, Paganoni G, Spinelli A, de Luca M, Pellegrini G. 

24. Kethiri AR, Basu S, Shukla S, Sangwan VS, Singh V. Optimizing the role of limbal explant size and source in determining the outcomes of limbal transplantation: an in vitro study. 

25. Levis HJ, Daniels JT. Recreating the human limbal epithelial stem cell microenvironment for stem cell niche. 

26. Chameettachal S, Prasad D, Parekh Y, et al. Prevention of corneal myofibroblastic differentiation in vitro using a biomimetic ECM hydrogel for corneal tissue regeneration. 

27. Gattazzo F, Urciuolo A, Bonaldo P. Extracellular matrix: a dynamic microenvironment for stem cell niche. 

28. Ghezzi CE, Marelli B, Omenetto FG, Funderburgh JL, Kaplan DL. 3D in vitro corneal tissue model with epithelium, stroma, and innervation. 

29. Wang S, Ghezzi CE, Gomes R, Pollard RE, Funderburgh JL, Kaplan DL. In vitro 3D corneal tissue model with epithelium, stroma, and innervation. 

30. Tsai RJ, Tseng SC. Limbal autograft transplantation for ocular surface disorders. Ophthalmology. 1989;96:709-722. 

31. Dua HS, King AJ, Joseph A. A new classification of ocular surface classification, diagnosis, and staging of limbal stem cell deficiency. 

32. Beheagel J, Ni Duhhghilll S, Koppen C, et al. Safety of cultivated limbal epithelial stem cell transplantation for human corneal regeneration. 

33. Kong B, Chen Y, Liu R, et al. Fiber reinforced GeIMA hydrogel to induce the regeneration of corneal stroma. 

34. Wang S, Ghezzi CE, Gomes R, Pollard RE, Funderburgh JL, Kaplan DL. In vitro 3D corneal tissue model with epithelium, stroma, and innervation. 

35. Wang S, Ghezzi CE, Gomes R, Pollard RE, Funderburgh JL, Kaplan DL. In vitro 3D corneal tissue model with epithelium, stroma, and innervation. 

36. Wang S, Ghezzi CE, Gomes R, Pollard RE, Funderburgh JL, Kaplan DL. 3D functional corneal stromal tissue equivalent based on corneal stromal stem cells and multi-layered silk film architecture. 

37. Ghezzi CE, Marelli B, Omenetto FG, Funderburgh JL, Kaplan DL. 3D functional corneal stromal tissue equivalent based on corneal stromal stem cells and multi-layered silk film architecture. PLoS One. 2017;12:e0169504.
52. Schwab IR, Reyes M, Isseroff RR. Successful transplantation of bioengineered tissue replacements in patients with ocular surface disease. Cornea. 2000;19:421-426.

53. Sacchetti M, Rama P, Bruscolini A, et al. Limbal stem cell transplantation: clinical results, limits, and perspectives. Stem Cells Int. 2018;2018:8086269.

54. Sangwan VS, Basu S, Vemuganti GK, et al. Clinical outcomes of xenofree autologous cultivated limbal epithelial transplantation: a 10-year study. Br J Ophthalmol. 2011;95:1525-1529.

55. Baylis O, Figueiredo F, Henein C, Lako M, Ahmad S. 13 years of cultured limbal epithelial cell therapy: a review of the outcomes. J Cell Biochem. 2011;112:993-1002.

56. Haagdorens M, Van Acker SI, Van Gerwen V, et al. Limbal stem cell deficiency: current treatment options and emerging therapies. Stem Cells Int. 2016;2016:9798374.

57. Basu S, Ali H, Sangwan VS. Clinical outcomes of repeat autologous cultivated limbal epithelial transplantation for ocular surface burns. Am J Ophthalmol. 2012;153:643-650.

58. Pellegrini G, Ardigo D, Milazzo G, et al. Navigating market authorization: the path holoclar took to become the first stem cell product approved in the European Union. Stem Cells Transl Med. 2018;7:146-154.

59. Thokala P, Singh A, Singh VK, et al. Economic, clinical, and social impact of simple limbal epithelial transplantation (SLET) for limbal stem cell deficiency (LSCD). Br J Ophthalmol. 2021; (in press).

60. Schlereth SL, Hos D, Matthaei M, et al. New technologies in clinical trials in corneal diseases and limbal stem cell deficiency - review from the European Vision Institute (EVI) Special Interest Focus Group Meeting. Ophthalmic Res. 2020;64:145-167.

61. De Luca M, Pellegrini G, Green H. Regeneration of squamous epithelia from stem cells of cultured grafts. Regen Med. 2006;1:45-57.

62. Sangwan VS, Basu S, MacNeil S, Balasubramanian D. Simple limbal epithelial transplantation (SLET): a novel surgical technique for the treatment of unilateral limbal stem cell deficiency. Br J Ophthalmol. 2012;96:931-934.

63. Basu S, Sureka SP, Shanbhag SS, Kethiri AR, Singh V, Sangwan VS. Simple limbal epithelial transplantation: long-term clinical outcomes in 125 cases of unilateral chronic ocular surface burns. Ophthalmology. 2016;123:1000-1010.

64. Vazirani J, Ali MH, Sharma N, et al. Autologous simple limbal epithelial transplantation for unilateral limbal stem cell deficiency: multicentre results. Br J Ophthalmol. 2016;100:1416-1420.

65. Arora R, Dokania P, Manudhane A, Goyal JL. Preliminary results from the comparison of simple limbal epithelial transplantation with conjunctival limbal autologous transplantation in severe unilateral chronic ocular burns. Indian J Ophthalmol. 2017;65:35-40.

66. Queiroz AG, Barbosa MM, Santos MS, Barreiro TP, Gomes JA. Assessment of surgical outcomes of limbal transplantation using simple limbal epithelial transplantation technique in patients with total unilateral limbal deficiency. Arq Bras Oftalmol. 2016;79:116-118.

67. Jackson CJ, Myklebust Erno IT, Ringstad H, et al. Simple limbal epithelial transplantation: current status and future perspectives. Stem Cells Transl Med. 2020;9:316-327.

68. Basu S, Mohan S, Bhalerao S, Singh V, Sangwan V. Simple limbal epithelial transplantation (SLET) in failed cultivated limbal epithelial transplantation (CLET) for unilateral chronic ocular burns. Br J Ophthalmol. 2018;102:1640-1645.

69. Utheim TP, Aass Utheim O, Salvanos P, et al. Concise review: altered versus unaltered amniotic membrane as a substrate for limbal epithelial cells. Stem Cells Transl Med. 2018;7:415-427.

70. Shanbhag SS, Nikpoor N, Rao Donthineni P, Singh V, Chodosh J, Basu S. Autologous limbal stem cell transplantation: a systematic review of clinical outcomes with different surgical techniques. Br J Ophthalmol. 2020;104:247-253.

71. Mednick Z, Boutin T, Einan-Litshitz A, Sorkin N, Slomovic A. Simple limbal epithelial transplantation for recurrent pterygium: a case series. Am J Ophthalmol Case Rep. 2018;12:5-8.

72. Kaliki S, Mohammad FA, Tahiliani P, Sangwan VS. Concomitant simple limbal epithelial transplantation after surgical excision of ocular surface squamous neoplasia. Am J Ophthalmol. 2017;174:68-75.

73. Samoila O, Gocan D. Clinical outcomes from cultivated allogenic stem cells vs. oral mucosa epithelial transplants in total bilateral stem cell deficiency. Front Med. 2020;7:43.

74. Susainanickam PJ, Maddleti S, Pulimamidi VK, et al. Generating minicorneal organoids from human induced pluripotent stem cells. Development. 2017;144:2338-2351.

75. Daya SM. Conjunctival-limbal autograft. Curr Opin Ophthalmol. 2017;28:370-376.

76. Clare G, Suleman H, Bunce C, et al. Amniotic membrane transplantation for acute ocular burns. Cochrane Database Syst Rev. 2012;107:980-989.

77. Nishida K, Yamato M, Hayashida Y, et al. Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium. N Engl J Med. 2004;351:1187-1196.

78. Nakamura T, Takeda K, Inamoto T, Sotozono C, Kinoshita S. Long-term results of autologous cultivated oral mucosal epithelial transplantation in the scar phase of severe ocular surface disorders. Br J Ophthalmol. 2011;95:942-946.

79. Shanbhag SS, Senthil S, Mohamed A, Basu S. Outcomes of the Boston type 1 and the Aurolab keratoprosthesis in eyes with limbal stem cell deficiency. Br J Ophthalmol. 2020;105:473-478.

80. Rohaina CM, Then KY, Ng AM, et al. Reconstruction of limbal stem cell deficient corneal surface with induced human bone marrow mesenchymal stem cells on amniotic membrane. Transl Res. 2014;163:200-210.

81. Harkin DG, Foy L, Bray LJ, Sutherland AJ, Li FJ, Cronin BG. Concise reviews: can mesenchymal stromal cells differentiate into corneal cells? A systematic review of published data. Stem Cells. 2015;33:785-791.

82. Yazdanpanah G, Jabbehdari S, Djalilian AR. Emerging approaches for ocular surface regeneration. Curr Ophthalmol Rep. 2019;7:1-10.

83. Ghoubay D, Borderie M, Grieve K, et al. Corneal stromal stem cells vs. oral mucosa epithelial transplants in total bilateral stem cell deficiency. Br J Ophthalmol. 2018;102:1640-1645.

84. Basu S, Hertsenberg AJ, Funderburgh ML, et al. Human limbal biopsy-derived stromal stem cells prevent corneal scarring. Sci Transl Med. 2014;6:266ra172.

How to cite this article: Singh V, Tiwari A, Kethiri AR, Sangwan VS. Current perspectives of limbal-derived stem cells and its application in ocular surface regeneration and limbal stem cell transplantation. STEM CELLS Transl Med. 2021;10:1121-1128. https://doi.org/10.1002/stcm.20-0408